CategoriesWACI Health News

Africa CDC: Great Opportunity for New AU Chair to Transform Africa’s Health

In February, Africa elected Chad’s Moussa Faki Mahamat as the new chairperson of the African Union Commission (AU) replacing South Africa’s Nkosazana Dlamini-Zuma.

One of the most remarkable advances in global health under the leadership of Dlamini-Zuma, was the formation of the Africa Centers for Disease Control and Prevention, a public health agency to lead the transformation of Africa’s health.

The birth of Africa CDC is timely and crucial because it will address the uneven burden of disease as evident in sub-Saharan Africa that carries 11 percent of the world’s population but 24 percent of disease burden as per the AU Commission Strategic Plan 2014-2017.

As the secretariat to the Civil Society platform for Health in Africa (CISPHA), we are elated to witness the formation of this historic initiative – which Africa’s civil society advocated for vigorously.

It is a significant opportunity for Africa to improve the health of its people – a key element in shaping the continent’s sustainable development. We urge Mahamat to strengthen this new outfit and anchor it as a centerpiece of his leadership.

The weakness of many institutions in Africa lack of clear leadership and sufficient resources. We hope that the chairperson will give the agency the support it needs – both in leadership and in resources – to allow it to achieve its mandate of achieving better health for the people of the continent.

CategoriesArticle

New Beginnings for HIV Prevention Research in Africa

Advances in science in the last two decades have led to tremendous progress against HIV. Breakthroughs in HIV treatment and prevention research have allowed the HIV community to halt and begin to reverse spread of the HIV epidemic. Biomedical approaches such as rapid and user-friendly HIV tests and affordable and effective antiretroviral treatment for people living with HIV have changed the landscape of the HIV response. Other impactful prevention tools have included voluntary medical male circumcision, male and female condoms, and oral pre-exposure prophylaxis (PrEP), among others.

All the same, the fight against HIV is far from won. HIV prevention efforts across the world have all but stagnated. According to UNAIDS, 2.1 million people became newly infected with HIV around the world in 2015. To end HIV as an epidemic by 2030, the world will need to do more, deploying traditional tools while developing new tools to accelerate the fight against the disease.

Research and development around new tools to help bolster HIV response is fundamental. It is why a new initiative called the Coalition to Accelerate and Support Prevention Research (CASPR) is exciting. Funded by USAID, and supported by PEPFAR, the coalition seeks to strengthen Africa-focused and led HIV biomedical prevention research, implementation and advocacy. The fact that the coalition is Africa focused is also fundamental because Africa has been left behind in many research and development issues.

The CASPR network, led by AVAC, brings together several Africa-based partners—including the Research institute of the University of the Witwatersrand (WRHI), WACI Health, HIV/AIDS Vaccine Ethics Group (HAVEG), the New HIV Vaccine and Microbicide Advocacy Society (NHVMAS) and the Advocacy for Prevention of HIV and AIDS (APHA)– to accelerate HIV prevention research in Africa. These groups along with partners with longstanding engagement in the region, including IAVI, FHI 360, Avenir Health, and Internews, will work collaboratively to build a network  dedicated to advancing advocacy, policy, regulatory, community engagement and communications efforts that help accelerate biomedical HIV prevention research.

This initiative will support Africa to make its contribution in HIV prevention research, in areas such  vaccine development. This is much needed. Africa can play its role, not only advocating for great use of the tools available to defeating HIV but also in contributing to creation of new tools to end the disease as an epidemic.

CASPR seeks to support an Africa-centered network dedicated to advancing biomedical HIV prevention research through a robust network of strategic partnerships and an interconnected array of activities such as linking prevention research advocacy to campaigns for increased domestic financing for health; establishing an African HIV Media Network; expanding the Good Participatory Practice framework; and increasing coordination between research partners, governments and civil society.

CategoriesArticle

Big Stories of 2016

WACI Health reflects on the major developments in global health in 2016.

  1. In May 2016, WHO recommended a shorter treatment for multi-drug resistant TB, which not only reduces the length of treatment by half for many patients but also cuts costs by at least 50 percent.  Full story

  2. In September, the World Health Organization certified Sri Lanka as a malaria-free nation. Full story

  3. In September, the Global Fund raised close to US$13 billion to accelerate the response to HIV, TB and malaria as well as build resilient and sustainable systems for health. Full story

  4. In October, the world launched the first child-friendly TB medicines. The new formulations will increase children’s adherence to the drugs as they are easier for children to take. Full story

  5. In November, trials for a new HIV vaccine started in South Africa. Full story

  6. In December, a new Ebola vaccine was found to give 100 percent protection against the disease. Full story
CategoriesWACI Health News

Press Release Combating TB-HIV in South Africa World AIDS Day 2016

press release waci healtjh

new research report from ACTION shows that while countries have taken steps in the right direction to combat the deadly duo of TB and HIV, policy improvements have not all translated into changes at the facility level.

The report, From Policy to Practice: How the TB-HIV Response is Working launched at the International AIDS conference in July 2016, affirms that of all the countries with high burdens of HIV-associated TB, the government of South Africa has most fully embraced TB-HIV integration and actively taken steps to implement collaborative activities. Support for TB-HIV collaboration flourishes within the Ministry of Health, who was the first country to develop a joint strategic plan for HIV, TB, and STIs.

South Africa’s government has been incredibly innovative in its fight against TB and HIV, and has recently begun to implement the recommendations in South African HIV and TB Investment Case published in March 2016. This investment case, which began as a requirement for a Global Fund HIV proposal and was taken further by the government, affirms that HIV and TB represent among the most serious of all health threats to the people of South Africa. South Africa is also in a unique position among high burden countries to scale up R&D for new diagnostics and treatments.

Despite the country’s strong efforts to fight TB and HIV, the report highlights a key challenge: A health system fractured between overburdened public clinics and well-resourced private providers accessible only to elites means that many people who need services are being left behind. To address inequity, South Africa is rolling out a national health insurance financing system over the next 14 years and is working to address quality of care in public clinics.4,5 For the “ideal clinic” concept to be realized, public health facilities, especially at the primary health care level, need to be resourced (i.e., financially and staffing-wise, with trainings to build capacity, and dissemination and implementation of new guidelines and policies).

On this World AIDS Day, ACTION partner WACI Health in collaboration with TB/HIV Care Association proposes to creating a moment where recommendations from the report From Policy to Practice: How the TB-HIV Response is Working along with the case study Combating TB-HIV in South Africa can be brought to relevant stakeholders including government, donors and civil society. This event will be taking place in Mdantsane NU 1 Community hall on the 8th of December 2016 from 9h30.

The key messages are as follows:

  1. The South Africa government should increase investment in research and development by 33 percent to support the advancement of new tools to fight TB and TB-HIV.
  2. The Ministry of Health should work with primary health care facilities to support the implementation of TB-HIV policies.
  3. Donors should continue to invest in high impact TB-HIV interventions and support sustainable national programs.
  4. Civil society must work to promote equitable access to care and support community-based responses to TB-HIV care

For further information, please contact:

Sizwe Nombasa Gxuluwe, Waci health, email: nombasa@wacihealth.org, Cell:082640554

CategoriesArticle

Highlights of the Year

In our advocacy work over the last year, our partnership has accumulated a list of accomplishments and as a result propelled our vision of advocating for improved health for all in Africa. Below is a select few of those 2016 highlights.

High-Level Meeting in New York: CISPHA co-hosted a pan-African civil society meeting ahead of the United Nations High Level Meeting on HIV, playing a significant role in urging partners to commit to improved financing of the Aids response by ensuring that the Global Fund is funded strongly. The outcome document from the meeting became a critical reference text for both the Africa Union member states and donor governments. The deliberations are captured in this blog by GFAN Africa.

Kenya Contribution to Global Fund: Together with KANCO, WACI Health and the Kenyan civil society organizations we worked to engage Kenya Ministry of Health officials, including Cabinet Secretary for Health Dr. Cleopa Mailu and Acting Director of Medical Services Dr. Jackson Kioko. These leaders committed to advocate for an increased Kenyan pledge to the Global Fund replenishment. The objective came to fruition with a pledge of US$ 5 million by Kenya during the pledging conference in Montreal, Canada 16-17, September 2016.

Vaccines: In commemoration of the 2016 World AIDS Vaccine Day, WACI Health co-convened civil society representatives from the eastern and southern Africa region to renew, strength and accelerate civil society action on investments and innovation in AIDS Vaccine Research and Development, among other New Prevention Technologies. This meeting came up with a call to action, boldly calling upon African governments to accelerate HIV R&D investments

 

CategoriesArticle

Global Fund Replenishment and CISPHA’s Journey

A great thing happened in Africa civil society circles in 2009 with the formation of CISPHA – the Civil Society Platform for Health in Africa. In seven short years, the group has covered a lot of ground, uniting many civil society organizations working in global health in Africa, demanding a space at the table, and articulating issues that nudge governments and other authorities to do more for the health of the people of the continent.

With remarkable experience forged in the trenches of global health advocacy, CISPHA has spent the last year firmly focused on the Sustainable Development Goals (SDGs) launched in New York in September 2015.

The framing of the SDGs was greatly successful in its eloquent capturing of the fact that all issues of development are interconnected.  While CISPHA has chosen to focus its work on SDG3 – ensure healthy lives and promote well-being for all at all ages – it recognizes that to attain that goal there are many other fundamental factors covered in other SDGs that must come to play. Issues of poverty, education, gender equality, human rights, climate change, among others. As such, CISPHA seeks to build broader and richer partnerships for development.

In 2016, CISPHA focused much of its energy on GFAN Africa in supporting the replenishment of the Global Fund to Fight AIDS, Tuberculosis and Malaria – a partnership that has saved more than 20 million lives in the last 15 years of its operations. CISPHA regards the Global Fund as one of the most successful partnerships for development.

In 2016, the Global Fund held its replenishment to raise US$ 13 billion to accelerate the fight against HIV, tuberculosis and malaria and to build resilient and sustainable systems for health. A strong Fifth Replenishment for the Global Fund’s was one of CISPHA’s top objectives in 2016. The network lobbied and advocated for more support for the fight against HIV, tuberculosis and malaria, reminding governments of the impressive gains made against these diseases because of the work of the Global Fund partnership. It was time to accelerate that progress and end these diseases for good. CISPHA also mapped out reasons why the gains were fragile and why the world could not stop investing in the Global Fund.

It was exciting when we gathered in Montreal in September — in a meeting hosted by Prime Minister Justin Trudeau of Canada to see partners raise US$ 12.91 billion for the Global Fund. The amount raised — nearly meeting the US$ 13 billion goal — was the biggest commitment of funds to fight diseases in history. It was a remarkable feat especially in a time of many competing global priorities.

The African civil societies were especially gratified by the fact that for the first time African countries were front and center in galvanizing the world to invest more in the Global Fund. Beyond calling on the world to commit more resources to the Global Fund, African countries also made strong pledges themselves. Benin, Côte d’Ivoire, Kenya, Namibia, Nigeria, Senegal, South Africa, Togo, and Zimbabwe, Zambia, South Africa each made their contributions. The money raised will save 8 million lives, avert 300 million infections – most of them in Africa – and help build resilient and sustainable systems for health.

For CISPHA, which has committed itself to calling on Africa to invest more in the health of its people, this was a remarkable achievement. Nevertheless, we are not there yet. CISPHA now calls on African governments to commit more of their annual expenditures to health as demanded by Africa Scorecard on Domestic Financing for Health launched in July this year.

For now, CISPHA is thankful for the remarkable achievement in raising funds for the Global Fund, now expected to go beyond the US$ 13 billion. Above all, CISPHA is tremendously thankful for the strong showing of African countries in the Replenishment. For every, civil society group or partner that advocated to make this possible we thank you. We are looking forward to more such successes in 2017 and beyond.

CategoriesArticle

A New Hat

In 2016 – after close to 20 years as World Aids Campaign International (WACI) – we rebranded, streamlining our mandate and renaming our organization WACI Health. As an Africa regional advocacy organization, WACI Health has taken a firm focus on ending life-threatening illnesses and improving health for all on the African continent. We aim to build broad collaborations that can galvanize sufficient political will to enhance and guarantee health equity, foster human rights and promote gender equality.

Our approach is three-pronged:

  • Policy and advocacy
  • Capacity strengthening for civil society, for stronger engagement in global health
  • Civil society mobilization

Our footprints

In 1997, we began as World AIDS Campaign (WAC) with an aim to raise public awareness on the global Aids response, working amongst diverse civil society organizations. We led in the planning and observance of the International World Aids Day. Four years later, we became an independent non-governmental organisation based in the Netherlands.

In 2008, we undertook a strategic shift that led to the registration of World Aids Campaign International (WACI) in South Africa. Over the years, our scope of work has also increased from a HIV and Aids portfolio to an all-inclusive health advocacy package for Africa, with a broader, approach to inclusive health needs of people.

In 2016, we rebranded to WACI Health. Wearing this new hat, we have stayed true to our traditional role of responding to HIV and Aids even as we embrace a broader health development agenda.

CategoriesArticle

Who We Are

About us

WACI Health is an Africa regional advocacy organization committed to creating political will to end life-threatening epidemics and improve health for all in Africa.

Our History

We started out as World AIDS Campaign (WAC) in 1997, to focus on raising public awareness on specific issues on the global AIDS response. This was achieved by working to support and strengthen campaigning on HIV accountability among diverse civil society constituencies worldwide.

WACI was also tasked to lead the planning and observance of the International World Aids Day. In 2004, became an independent NGO based in the Netherlands.

In 2008, the organization undertook a strategic shift that would lead to the registration of World Aids Campaign International  (WACI) in South Africa. Over the following (4) years, WACI would see a range of institutional and leadership transitions. From a global organization, founded and headquartered in Europe, working in various geographical regions, including: Europe, Africa, Asia, Middle East and North Africa, to an organization that is today based and focused on Africa addressing not only HIV but also broader issues in health.

The organization’s deliberate shift to focus on Africa was guided by the need to be more conscientious, more innovative and even more accountable and streamlined in our approaches as we continued to ensure that the organization maintained her pivotal role in the global AIDS response, while continually embracing and incorporating the broader health development agenda into her work.

After seven (7) years as World AIDS Campaign International, the organization is now referred to as ‘WACI Health’.

 

Vision

Health for all in Africa

Mission

WACI Health exists to champion the end of life-threatening epidemics and health for all in Africa by influencing political priorities through an effective, evidence-driven Pan-African civil society voice and action.


Our Strategic Approach

In our transition from World AIDS Campaign International to WACI Health, we remain committed to responding vigorously to epidemics such as AIDS, TB and malaria as well as associated causes of death. In addition, the shifting field of global health calls us to support long-term investments in health and explore the interconnectedness of major infectious diseases and conditions that continue to kill many across the world. At the core of our strategy is a deliberate intention to broadly contribute to health equity, human rights and gender equality.

Our approach is based on our theory of change, which is made up of three core strategies:

  1. Policy and advocacy: Policy watch and analysis for strategic input and accountability at global, regional and national levels. Through political advocacy, we will seek to influence perceptions, views and decisions of those in positions of power. We will continually seek to achieve improved tools for data analysis and evidence for advocacy.
  2. Civil society Capacity Strengthening: Strengthening capacity of Civil Society to engage as strong advocates for health in Africa. We will support realization of appropriate civil society capacity for utilization of tools, and knowledge to apply evidence in advocacy. We will seek to strengthen civil society and community organizing for health advocacy.
  • Civil society mobilization: Building a civil society movement in Africa in order to raise a critical mass of people whose voices and action will be core to ending the epidemics and improving health for all in Africa. We envisage a movement that will broadly contribute to health equity, human rights and gender equality.

The theory of change is dynamic and interactive, with all of the strategies working together to impact 3 areas of Global Health work, which broadly point to our strategic goals.

 

  1. Resources for health: We will focus on urging national governments and international agencies to step up their investments in health through transparent investments.
  2. Research and Development: We will focus on supporting health research and development with an aim to see that its application and delivery results to access to health products, technologies, innovations and better health for the people most in need.
  • Civic Engagement: We will strive to support stronger civil society and community voice and action. We see this strengthening/empowerment not only as a process in health advocacy but also an end in itself where empowerment contributes to sustainability beyond specific processes.
CategoriesArticle

African Countries Step Up Contributions to the Global Fund

GENEVA – African countries increased investments in the Global Fund as global health partners seek to galvanize all sources of funding to end AIDS, tuberculosis and malaria as epidemics, and to build resilient and sustainable systems for health.

Benin, Côte d’Ivoire, Kenya, Namibia, Nigeria, Senegal, South Africa, Togo, and Zimbabwe each made contributions to the Global Fund’s Fifth Replenishment, hosted by Prime Minister Justin Trudeau of Canada in Montreal on 16-17 September. Altogether, the conference secured pledges of more than $12.9 billion from partners across the world.

Pledges by African countries to the Global Fund are aligned with a far more significant increase of domestic investment in health by African countries – US$10.9 billion committed for 2015-17. For the first time, Africa is now mobilizing more domestic funding for health than foreign funding in the sector.

Specific pledges to the Global Fund signal commitment beyond any specific country, toward a global approach to ending the epidemics.

President Faure Gnassingbé of Togo, making his nation’s first contribution to the Global Fund of US$1 million, said Togo will play its part in the fight against epidemics to end them for good.

President Macky Sall of Senegal said: “In an interconnected and interdependent world, diseases know no borders.” He added: “New impetus is needed to continue support to the countries affected by diseases. These countries should also invest more in the health sector so we can end these diseases for good.”

President Alassane Ouattara of Cote d’Ivoire also pledged US$1 million to the Global Fund, and spoke about the importance of focusing investments in programs that specifically address the disproportionate effects on women and girls.

President Uhuru Kenyatta of Kenya, when he announced a pledge of US$5 million just prior to the Replenishment Conference, said his country was contributing the funds in the spirit of solidarity and shared responsibility in the fight against diseases.

“The funds, which will be invested in prevention and treatment of diseases and in building health systems, will save lives and create more inclusive and thriving communities,” President Kenyatta said.

Mark Dybul, Executive Director of the Global Fund, said more investments in health by African countries have helped build remarkable momentum against HIV, tuberculosis and malaria – some of Africa’s most devastating diseases.

“African leaders have made investing in health a top priority,” Dr. Dybul said. “They are strong partners in a global movement that is determined to expand access to health services to everyone, leaving no one behind.”

The Replenishment Conference raised nearly $1 billion more than the previous pledging session in 2013, and benefitted from participation by leaders from countries all over the world, including heads of state of Senegal, Côte d’Ivoire and Togo and the prime ministers of Mali and Guinea.

The amount raised will save 8 million lives, avert 300 million infections, and help build resilient and sustainable systems for health. The conference is the beginning of a three-year replenishment period, and the Global Fund will work to gain further contributions in the coming months and years, with strong advocacy by civil society and partners worldwide.

###

For more information, please contact:

ERNEST WAITITU
Editorial Specialist
Mobile: +41 079 541 0656
E-mail: ernest.waititu@theglobalfund.org

CategoriesWACI Health News

Accelerating research through funding, crucial to defeating AIDS

Nairobi, May 17-18 2016. In commemoration of the 2016 World AIDS Vaccine Day, representative civil society groups from the Eastern and Southern Africa (ESA) region convened to re-invigorate and accelerate Civil Society Action on investments and innovation in AIDS Vaccine Research and Development among other New Prevention Technologies (NPTs).

The timing of this meeting, hosted by WACI Health, KANCO, MANASO, EANNASO in partnership with IAVI, coincided with the process for the High Level Meeting on HIV&AIDS- a process that would lead to the endorsement of a political declaration reiterating commitment by UN member states to bring about an end to the AIDS epidemic.

Africa civil society had agreed to a common civil society regional position on the HLM, which included this specific language on preventive vaccines:Boldly pursue new scientific solutions and expand investment in research and development for improved diagnostics, easier and more tolerable treatment regimens, preventive and therapeutic vaccines, and other prevention technologies as well as a functional cure.

Is Prevention being left behind?

This particular language and demand, which set the tone for the 2 day’s meeting, had been inspired by concerns over slowed but not reversed tide of new HIV infections. As noted by Ms. Jacquline Makokha, UNAIDS Regional Support Team for Eastern and Southern Africa, in her remarks callingupon CSOs to join UNAIDS in its efforts to revitalize HIV prevention. She added that in overall, provision of large scale, effective HIV prevention interventions were yet to be optimized, hence the slow reduction of new infections. She further noted that with funding for prevention dwindling, fewer than one in five people at risk of HIV infection today has access to prevention programs.She elaborated on theUNAIDS quota for prevention campaign, which calls for 25% of all funding for HIV/AIDS programs to prevention efforts.

Still too many new infections

While prevention approaches including condoms, VMMC, antiretroviral treatment as prevention (TasP) and PrEP have brought about substantial reductions in new HIV infections, with a record of 14% decline in ESA region between 2010-2015, there are still too many people becoming infected worldwide to bring the epidemic to a halt. According to UNAIDS 2016 data, 2.1 million people became newly infected with HIV in 2015, globally. Eastern and Southern Africa is home to 960,000 of those, accounting for 46% of the global total of new HIV infections.

Need for new tools

The need for new tools to bolster existing strategies for prevention and ultimately end the pandemic is undeniably of paramount importance.  Glenda Gray, President of the South African Medical Research Council, and colleagues,in their paper on ending AIDS, argue that the widespread elimination of HIV will require the development of new, more potent prevention tools. The paper goes further to point out that true containment of the epidemic requires the development and widespread implementation of a scientific advancement that has eluded us to date—a highly effective vaccine. A safe, effective, licensed, affordable and accessible vaccine would help to sustain the impact of expanded access to existing treatment and prevention options.

Dr Borna Nyamboke of KAVI Institute of Clinical Research, in her remarks further stressed that efforts to ensure broader access to HIV testing and treatment as well as existing and emerging HIV prevention options must go hand-in-hand with efforts for additional ways to prevent HIV, including a vaccine.‘Indeed, there are now more tools than ever to help control the HIV epidemic, but an HIV vaccine remains a critical component of the long-term strategy for ultimately ending the epidemic.’

Long timeframe for availability; planning for access

While vaccine development is a slow, iterative process, now 35 years into the HIV epidemic, researchers believe that an HIV vaccine is closer than ever,given the probable start of new vaccine efficacy trials in 2016/2017. Results from theseefficacy trials would likely not be available until 2021. In addition, positive results are just the beginning of making a vaccine available to those who need it. Moving from trial results to licensure, wide-scale manufacturing and rollout plans can add several years to the process. Therefore, planning for access after positive results should take place in parallel with the research.

Advocates, donors, policymakers, regulators and funders all have a role to play in planning now to ensure that positive results from a trial are translated as quickly as possible to a safe, effective, licensed and widely accessible HIV vaccine.

HIV Prevention R&D Investment

Research on HIV&AIDS is identified as important in HIV and AIDS response world over with hopes for advanced treatment, vaccine, and a cure being purely hinged on HIV&AIDS Research. However, overall funding has remained at nearly the same level for approximately a decade. In 2015, preliminary reported funding for HIV prevention R&D decreased from US$ 1.25 billion in 2014 to US$1.18 billion. Changing funding dynamics and priorities in donor countries have shaped these trends and will continue to do so in years to come.  Currently, neither national budgets nor regional commitments to health demonstrate adequate investment in new HIV prevention R&D.

DrNdukuKilonzo, the Director of the Kenya National AIDS Control Council, speaking to the 36 CSO leaders from 13 countries in the ESA region, in her opening remarks made reference to NACC’s leadership towards increased investments for HIV research agenda in Kenya- an initiative that could be replicated in other African countries. NACC’s policy brief on domestic financing of the HIV and AIDS research agenda provides guidance on the policy directions required to ensure a greater return on investment. Most notably NACC willwork to ensure commitments of allocation of 2% of GDP to the National Research Fund (NRF) and 10% of total HIV spending to HIV research are materialized

Civil society role and commitment

Thirty six CSO leaders from 13 countries in the ESA region gathering in commemoration of WAVD 2016 at this meeting, reiterated their commitment to addressing HIV&AIDS, and a world without AIDS. To achieve that vision, civil society must not lose sight of two things:

  • Making maximum use of the prevention and treatment strategies available right now.
  • Investing in research and development of critically needed new prevention options.

The group further called Civil Society in Africa to strengthen and sustain momentum to support innovation and accelerate research & development toward new prevention options (like vaccines and microbicides), better treatment therapies, and a cure. The meeting underscored the need for Civil Society and communities to continue to discuss and share experiences on how CSOs are transitioning to respond to HIV R & D needs in the quest for an end to AIDS.

CS committed to step up advocacy and issued a call to action, boldly calling upon African governments to accelerate HIV R&D investments through:

  1. Budgetary allocation of at least 15% of national budgets to health so as to increase funding to accelerate R&D for newer and improved health technologies including HIV new prevention technologies.
  2. Budgetary allocation of at least 2%of ministries of health budget to research
  3. 10% of HIV allocations be earmarked for research
  4. 25% of HIV allocations be earmarked for prevention efforts

Rosemary Mburu is the Executive Director of WACI Health, which hosts the Africa Civil Society Platform on Health (CiSPHA) and GFAN Africa hub. WACI Health is an ACTION partner, a global health advocacy partnership.